A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: Icariin inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3
Significance: This study suggests, for the first time, that Icariin, by increasing the expression of its target gene, it may decrease the expression of Notch3. Thus, pharmacological formulations encompassing “Icariin or its analogues” may be used to treat pulmonary arterial hypertension.
Amount: $ 500*
Undisclosed information: How Icariin decreases the expression of Notch3
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for pulmonary arterial hypertension: Icariin, a flavanoid and phosphodiestrase-5 inhibitor, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 18/April/2015, 17.35, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org